Naturally Splendid Enterprises Ltd. (TSX-V: NSP, OTCQB: NSPDF, Forum) announced this week that Health Canada has now provided a Notice of Authorization to proceed with a phase 2 clinical trial for a potential COVID-19 treatment utilizing the target drug Cavaltinib with
Plasm Pharmaceutical Inc.
Cavaltinib has been shown to inhibit cytokines (proteins released by the body that coordinate the immune and inflammatory response against infection or other triggers, but can go into overdrive and such is the case-in the high-risk patients infected by the SARS -CoV-2virus behind the COVID-19 pandemic).
Naturally Splendid’s Chief Executive Officer Craig Goodwin called this a significant step forward in their pursuit of a COVID-19 treatment that was made even more important as additional waves of the virus continue to spread.
“The hope remains high that Cavaltinib will provide relief for those afflicted with COVID. We also anticipate the clinical trial to provide additional indications where Cavaltinib may be effective”.
For more on this trial, click
here.
The food manufacturing Company also appointed
Larry Gilmour to its Board of Directors this week. His career began in sales and marketing with internationally recognized brands such as Libby’s, Playtex Corp., and Black and Decker. He also owned and operated chain grocery outlets and was the owner / operator of a Super Valu grocery store and an IGA grocery store in Vancouver, BC.
He stated that he had the opportunity to observe the evolution of Naturally Splendid over the past few years.
“I truly believe the varied career I have had, with the skills and lessons learned in sales and marketing, as well as my direct experience in the retail grocery space, is a combination that will be a great fit with the existing team at Naturally Splendid”.
FULL DISCLOSURE: Naturally Splendid Enterprises Ltd. is a client of Stockhouse Publishing.